Robert is an Operating Partner at Khosla Ventures where he focuses on health care.
Prior to joining Khosla Ventures, Robert was President and Chief Executive Officer of Fulcrum Therapeutics from the year the company was founded in 2016 until his retirement in March 2021. From 2010 to 2015, Robert served as president and CEO of Epizyme, an oncology drug discovery and development company. Prior to joining Epizyme, Robert served as director of novel therapeutics at Broad Institute of MIT and Harvard from 2006 to 2010. Robert began his career at Merck where he held a variety of leadership positions over 23 years, culminating in the role of vice president, licensing and external research.
During his career, Robert has been instrumental in advancing more than 20 compounds from discovery into clinical development in multiple therapeutic areas, several of which are changing the lives of patients. Robert has over 30 years of industry and management experience.
Robert holds a bachelor’s degree in chemistry from Spring Arbor University and a Ph.D. in biochemistry from the University of Iowa. He completed postdoctoral studies at Johns Hopkins University.
Robert serves on the boards of Faeth Therapeutics, Fulcrum Therapeutics, Turnstone Biologics, HemoShear Therapeutics and Spring Arbor University.